Cellectis SA (http://www.cellectis.com) is a world-leading company in genome engineering and genome surgery. The company is focused on developing and producing custom meganucleases for in vivo DNA surgery and also provides new tools for rational reverse genetics and targeted recombination. Cellectis' products induce unique, site-directed, double-strand DNA breaks in living cell and can be used in a wide range of biotechnological and therapeutic applications.
A strong Patent portfolio
Cellectis holds exclusive rights to 148 patents and patent applications providing the company with a strong position in the field of homologous recombination (3 issued US patents) and meganucleases and uses thereof (18 issued US patents) both naturally-occurring and with engineered specificity. A significant part of this patent portfolio has been exclusively licensed by Institut Pasteur, which spun off the company in 2000.
Institut Pasteur, thanks to its work with pioneering groups in the filed, has a long history in the exploitation of methods of homologous recombination, a major scientific breakthrough (Nobel Prize 2007) and is today the assignee of cornerstone patents from the late 80's. Finally the team, which discovered meganucleases and published founding works on the I-SceI homing endonucleases leading to the constitution of the Cellectis proprietary patent portfolio, is from Institut Pasteur.
A strong scientific background
Teams involved in the discovery of meganucleases at Institut Pasteur and Cellectis have published tens of cornerstone publications in prestigious peer-review papers such as Cell, Nature, Science, PNAS, JBC or JMB. For the sole year 2007, Cellectis has published 5 important scientific publications in peer-review journals and 2 papers since the beginning of 2008.
A technology that deliver
|SOURCE Cellectis SA|
Copyright©2008 PR Newswire.
All rights reserved